Iovance Biotherapeutics announced on June 3, 2026, that the Therapeutic Goods Administration granted conditional approval of Amtagvi (lifileucel) for adult patients with unresectable or metastatic melanoma who have previously received a PD-1 blocking antibody, and, where applicable, a BRAF inhibitor with or without a MEK inhibitor for BRAF V600-mutant disease. The decision makes Australia only the third market globally to approve lifileucel and the first to do so specifically in the post-checkpoint, post-targeted therapy setting.

Lifileucel is a personalised, tumour-derived autologous T cell therapy produced from a patient’s own tumour-infiltrating lymphocytes. The manufacturing process involves surgical resection of tumour tissue, isolation and expansion of TIL populations ex vivo, and infusion back into the patient after a lymphodepletion conditioning regimen. The finished product is a single-use, patient-specific therapy, a class of treatment that bears little resemblance to conventional systemic oncology agents in both its biology and its logistics.

The TGA’s decision was supported by efficacy and safety data from the global, multicentre C-144-01 trial, a single-arm study in heavily pre-treated patients with advanced melanoma. In this population, where prognosis after failure of anti-PD-1 and BRAF/MEK inhibitors is poor, lifileucel demonstrated an objective response rate of approximately 31.5 percent, with some responses appearing durable at extended follow-up. Median overall survival in the trial exceeded 13 months.

Australia has particular clinical urgency around this approval. The country records approximately 17,000 new melanoma diagnoses annually and more than 1,500 deaths, placing it among the highest-burden nations globally on an age-standardised basis. Queensland, New South Wales, and Victoria carry disproportionate case loads, driven by population genetics and historical patterns of UV exposure. The majority of patients who progress after immunotherapy and targeted therapy have had limited options beyond cytotoxic chemotherapy.

Iovance is working to authorise its first Australian treatment centre. The therapy’s logistical requirements, including tumour harvest, centralised manufacturing, cryopreservation, and infusion facility credentialing, mean that initial access will be concentrated in major metropolitan cancer centres. The company has built analogous site infrastructure in the United States and Europe following earlier approvals.

The TGA’s conditional approval framework, which requires ongoing post-market data collection, aligns with the agency’s increasing willingness to enable earlier patient access for serious conditions where efficacy signals are compelling even if long-term data are maturing.

For Australian oncologists, lifileucel extends the treatment algorithm for a patient population that has historically faced a therapeutic cliff after second-line progression. Its arrival signals broader momentum behind cellular therapies for solid tumours, a class that has until now found its clinical footing primarily in haematological malignancies.